(Q36082100)

12 August 2017

1 reference

title

An evidence-based approach to understanding the pharmacological class effect in the management of prostatic diseases (English)

1 reference

12 August 2017

Christopher P Evans

1

1 reference

12 August 2017

Neil Fleshner

series ordinal

2

1 reference

12 August 2017

John M Fitzpatrick

series ordinal

3

1 reference

12 August 2017

Alexander R Zlotta

series ordinal

4

1 reference

12 August 2017

language of work or name

1 reference

1 April 2005

1 reference

12 August 2017

1 reference

12 August 2017

volume

95

1 reference

12 August 2017

issue

6

1 reference

12 August 2017

page(s)

743-749

1 reference

Evidence based medicine: what it is and what it isn't

12 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05390.X

Evidence-based medicine for the urologist

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05390.X

Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05390.X

Postvoid residual urine in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: pooled analysis of eleven controlled studies with alfuzosin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05390.X

Terazosin for treating symptomatic benign prostatic obstruction: a systematic review of efficacy and adverse effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05390.X

Tamsulosin for treating lower urinary tract symptoms compatible with benign prostatic obstruction: a systematic review of efficacy and adverse effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05390.X

A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05390.X

A randomized, double-blind crossover study of tamsulosin and controlled-release doxazosin in patients with benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05390.X

Comparison of prazosin, terazosin and tamsulosin in the treatment of symptomatic benign prostatic hyperplasia: a short-term open, randomized multicenter study. BPH Medical Therapy Study Group. Benign prostatic hyperplasia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05390.X

A comparative study of terazosin and tamsulosin for symptomatic benign prostatic hyperplasia in Japanese patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05390.X

Finasteride in the treatment of clinical benign prostatic hyperplasia: a systematic review of randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05390.X

Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05390.X

The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05390.X

Comparative efficacy of triptorelin pamoate and leuprolide acetate in men with advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05390.X

Goserelin versus orchiectomy in the treatment of advanced prostate cancer: final results of a randomized trial. Zoladex Prostate Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05390.X

Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05390.X

6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05390.X

Adjuvant hormone therapy in locally advanced and localized prostate cancer: three EORTC trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05390.X

Inflammatory breast carcinoma: the sphinx of breast cancer research.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05390.X

Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05390.X

Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05390.X

Phase III Trial Comparing Whole-Pelvic Versus Prostate-Only Radiotherapy and Neoadjuvant Versus Adjuvant Combined Androgen Suppression: Radiation Therapy Oncology Group 9413

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05390.X

Neoadjuvant hormonal ablative therapy before radical prostatectomy: a review. Is it indicated?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05390.X

Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: final report of a double-blind, randomized, multicenter trial. Casodex Combination Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05390.X

Tolerability of Antiandrogens in the Treatment of Prostate Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05390.X

10.1111/J.1464-410X.2005.05390.X

21 January 2018

Identifiers

DOI

1 reference

12 August 2017

1 reference